JP2016510738A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510738A5
JP2016510738A5 JP2015561314A JP2015561314A JP2016510738A5 JP 2016510738 A5 JP2016510738 A5 JP 2016510738A5 JP 2015561314 A JP2015561314 A JP 2015561314A JP 2015561314 A JP2015561314 A JP 2015561314A JP 2016510738 A5 JP2016510738 A5 JP 2016510738A5
Authority
JP
Japan
Prior art keywords
composition
item
continuous infusion
oral
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510738A (ja
JP6247708B2 (ja
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/043136 external-priority patent/WO2014143107A1/en
Publication of JP2016510738A publication Critical patent/JP2016510738A/ja
Publication of JP2016510738A5 publication Critical patent/JP2016510738A5/ja
Application granted granted Critical
Publication of JP6247708B2 publication Critical patent/JP6247708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561314A 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法 Active JP6247708B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/792,056 2013-03-09
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017197488A Division JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Publications (3)

Publication Number Publication Date
JP2016510738A JP2016510738A (ja) 2016-04-11
JP2016510738A5 true JP2016510738A5 (enExample) 2016-07-14
JP6247708B2 JP6247708B2 (ja) 2017-12-13

Family

ID=51537409

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015561314A Active JP6247708B2 (ja) 2013-03-09 2013-05-29 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2019137721A Active JP6840197B2 (ja) 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017197488A Withdrawn JP2018002739A (ja) 2013-03-09 2017-10-11 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法
JP2019137721A Active JP6840197B2 (ja) 2013-03-09 2019-07-26 虚血性事象を処置し、その発生率を低減させ、かつ/または予防する方法

Country Status (10)

Country Link
EP (2) EP3978002A1 (enExample)
JP (3) JP6247708B2 (enExample)
CN (2) CN115120606A (enExample)
AU (1) AU2013381855B2 (enExample)
BR (1) BR112015022070B1 (enExample)
CA (1) CA2904523C (enExample)
EA (1) EA034550B1 (enExample)
ES (1) ES2904256T3 (enExample)
PL (1) PL2964233T3 (enExample)
WO (1) WO2014143107A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
WO2018234565A1 (en) * 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679721B2 (en) 1993-02-10 1997-07-10 Astrazeneca Ab N-alkyl-2-substituted ATP analogues
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
CA2747310C (en) * 2008-12-30 2018-02-06 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
SG176295A1 (en) * 2009-06-16 2012-01-30 Cardoz Ab Crystalline form of pemirolast
WO2011060066A2 (en) * 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий

Similar Documents

Publication Publication Date Title
JP2018514534A5 (enExample)
JP2011520899A5 (enExample)
JP2013522303A5 (enExample)
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
JPWO2020111018A5 (enExample)
JP2019501881A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2016515586A5 (enExample)
JP2016516773A5 (enExample)
JP2017501154A5 (enExample)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP6359583B2 (ja) 肝細胞がんの予防及び/又は治療のための医薬
RU2018123718A (ru) Режимы дозирования мелфлуфена для раковых заболеваний
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2024028652A (ja) 造影剤誘発急性腎障害の予防および/または処置
JP2016505050A5 (enExample)
JP2020510043A5 (enExample)
JP2019507786A5 (enExample)
JP2016510738A5 (enExample)
JP2019178177A5 (enExample)
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
JP7758655B2 (ja) 組合せ
JP2019507785A5 (enExample)
JP2019535830A5 (enExample)
Roth The use of vasopressin bolus to treat refractory hypotension secondary to reperfusion during orthotopic liver transplantation